Enzyme ChE,cholinergic therapy and molecular docking: Significant considerations and future perspectives

Genomic organization and gene transcription

Cholinergic neurons catalyze the hydrolysis of the cholinergic neurotransmitter Acetylcholine. ¹ Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) classification depends on substrate specificity and inhibition. ¹ AChE and BChE belong to the cholinesterase enzyme family with a critical role in cholinergic and non-cholinergic signaling.^1,2 AChE is responsible for terminating neurotransmission and synaptic activity, whereas BChE handles detoxification and exhibits broader substrate specificity. Both enzymes share structural similarities.^1,2 AChE and BChE differ based on the enzyme structure, active site, efficiency, substrate, biochemical roles, and tissue distributions.^1–3 However, both share a common ancestor as a member of the cholinesterase family containing conserved structural domains essential for their catalytic activity, reflecting their evolutionary relationship.^4,5 AChE and BChE genes arise from a duplication event. ⁶ Potential therapeutics arise with knowledge about similarities and differences between cholinesterase (ChE). ¹

AChE is responsible for hydrolysis of the neurotransmitter acetylcholine (ACh) into choline and acetate at cholinergic synapses, terminating synaptic transmission.^1–6

BChE hydrolyzes butyrylcholine more efficiently than acetylcholine and can act on acetylcholine, although it is less specific than AChE and can hydrolyze different choline esters.^1–6

BChE has a role in drug and toxin metabolism, detoxifying organophosphates (used in pesticides and nerve agents), and metabolizing drugs in the liver. BChE is a physiological buffer of AChE hydrolysis. When AChE is inhibited and less efficient, it has clinical implications. Variations in BChE activity affect an individual’s response to certain drugs. ⁷

BChE is located in the liver and circulates in the blood plasma, while AChE is predominantly in the synaptic clefts, neuromuscular junction, and red blood cells.^1,8 The gene for BChE localizes on chromosome 3 (q26.1), while the AChE gene localizes on chromosome seven (q22.1), as shown in Figure 1.^9–11OPEN IN VIEWER

The genomic region of BChE spans around 70 kb and has four exons and three large introns, while the AChE gene spans seven kb and has six exons, Figure 2.^12,13OPEN IN VIEWER

Generally speaking, more than 90% of transcripts undergo alternative RNA processing to generate about 100,000 different proteins from about 20,000 human genes. ¹⁴

BChE consists of different molecular forms called G1 (monomeric globular), G2 (dimeric), and G4 (tetrameric) with identical catalytic subunits that are symmetrical, hydrophilic, globular, and primary soluble forms. Globular BChE occurs in asymmetric, membrane-bound forms that are amphiphilic and consist of tetramers (G4) anchored to membranes by a protein, proline-rich membranes anchor (PRiMA). ¹² Asymmetric collagen-tailed BChE contains tetramers of catalytic subunits attached to membranes by a triple helical, non-catalytic collagen anchor called A4, where two tetramers make up the A8 form and three A12 forms. ¹² Heteromeric multimers assemble with amino-terminal proline-rich attachment, and collagen Q. BChE structure forms are available in Figure 3. ¹² OPEN IN VIEWER

Acetylcholinesterase isoforms depend on alternative splicing and polyadenylation, Figure 4. ¹⁴ OPEN IN VIEWER

The cap site at the 5’ end of the AChE gene allows the usage of promoters in different tissues. ¹⁵ The AChE gene has 6 exons. The exons include 3 invariant exons (exons 2, 3, and 4) encoding the catalytic domain nucleus and variable 5’ and 3’ regions, Figure 3.^14,16 Exon 5 has two alternative splice sites (ss) 3’ ss: one at the boundary of intron 4. and exon 5a (proximal 3’ ss), and the other at the end of exon 5a and exon 5b (distal 3’ ss).^14,16 The catalyst units produced differ based on the carboxyl end. ¹⁰ Alternative 3’ end splicing assembles three AChE (T, H, R) isoforms. ¹⁴ However, apart from this form, many others exist. The joining of exons 4 and 5a results in the creation of a hydrophobic dimeric isoform, AChE-H. Isoform is expressed in hematopoietic cells anchored to the membrane by glycophosphatidylinositol. ¹⁴ The fusion of exons 4 and 5b generates a tetrameric isoform, AChE-T, which is expressed in muscle, and brain, and anchored to a proline-rich membrane (PRIMA) or a trimeric collagen K tail. ¹⁴ The AChE-R monomeric isoform occurs when the transcript non-excretes after exon 4. The AChE-R isoform is rare and regulated in acute stress in the mouse brain. ¹⁴ Tissue-specific alternative polyadenylation site (PAS) is 21.2 kb downstream of canonical PAS in mouse muscles and brains. ¹⁷ Splicing factors SRSF1 (SF2 / ASF) and SRSF2 (SC-35) ubiquitous express and influence upstream and downstream expression regulation of AChE-T to AChE-R. ¹⁴

The soluble form is prevalent in plasma, while the membrane forms in muscles and the brain. ¹⁸ So far, more than 70 natural mutations are present in the BChE gene, which affects catalytic function and protein expression. ¹⁹ Leukaemias, megakaryocytopoiesis, breast cancer cells, and insects contain natural amplification of the cholinesterase gene. ²⁰

SNPs in the non-coding 5′-untranslated region (5′-UTR) (rs1126680) and intron 2 (rs55781031) of the BCHE gene may play roles in the emergence and progression of AD and PD. ²¹ The most common genetic variant in the BChE gene is BChE-K substitution (c.1699G>A, p.A539T, rs1803274) associated with a lower level of BChE molecules in PL with decreased activity caused by the impaired quaternary organization of the tetramer. ²²

Cholinesterase inhibitors are a significant focus for drug development, especially for conditions involving cognitive decline and memory impairment. ²³ They offer a pathway for designing therapeutic agents to manage or potentially reverse symptoms. ²³ Variations in Che genes (such as those coding for AChE and BChE) can influence individual responses to drugs and diseases. ²⁴ Studying these polymorphisms aids in personalizing treatments and deepening our understanding of disease mechanisms. ²⁴ The reason for choosing the Che enzyme is the role of Che, especially AChE, in AD, which makes it a critical target for research. Studying Che can lead to the development of better therapeutic strategies for managing cognitive disorders.^25–27 Molecular mechanisms enable insight into neuronal signaling and pathology of physiological processes.^25–27 Enzyme is a potential drug target for disease treatment and managing toxicity, making them relevant in pharmacology and medical chemistry research.^25–27 Investigation of polymorphisms reveals how genetic differences impact drug efficacy, disease development, and therapy, making it significant for environmental and occupational health studies.^25–27 Based on the abovementioned information, we can conclude that the Che enzyme is a noteworthy molecule in neurotransmission, physiological processes, disease, and treatment, with multifaceted functions impacting health outcomes. We chose Che for this study due to its well-established role in neurodegenerative diseases and its potential as a therapeutic target. By examining the ChE structure, function, and inhibition, this research aims to support the creation of new therapeutic approaches for diseases like Alzheimer’s, where cholinergic dysfunction is a fundamental aspect of the disease’s pathology. Additionally, natural compounds that inhibit Che offer a promising avenue for developing safer and more effective treatments.

Structure of enzyme ChEs

AChE classifies as a serine hydrolase/esterase with an ellipsoidal molecular structure featuring a central β-sheet and lateral α-helices. ¹⁷ In the narrow and deep depression, five regions involved in substrate and inhibitor binding (Torpedo Californica) have 5 different traits:

(1) Catalytic triad residues: amino acids Serine 200, Histidine 440, and Glutamin 327, at the bottom of the gorge, which directly participates in the catalytic cycle. ²⁸

The BChE belongs to the α/β-fold family of proteins. The enzyme catalyzes the hydrolysis of esters such as cocaine, acetylsalicylic acid, and heroin. It is significant in scavenging occurring (physostigmine) and synthetic (organophosphate) anticholinesterases. ¹² Each human catalytic BChE subunit consists of 574 amino acid residues. The catalytic triad, set at the bottom of a 20 Å-deep gorge, includes serine 226, histidine 466, and glutamic acid 353, surrounded by six amino acids. In contrast, AChE features 14 amino acids in a similar region (Figure 1). Within the acyl pocket (A), the substrate’s acyl group reside, while tryptophan (W) creates an anionic site that facilitates interaction between the quaternary nitrogen and the anionic site. Substrates interact with aspartic acid (D) and tyrosine (Y) residues found at the lip of the active site gorge, Figure 5. ¹² OPEN IN VIEWER

The anionic site interacts with the choline nitrogen through tryptophan. Positively charged substrates interact with aspartic acid 70 and tyrosine 332. During catalysis, the acyl pocket holds the acyl group of choline esters in a place where lysine 286 and valine 288 line this pocket. ¹² BChE and AChE are glycoproteins where complex carbohydrates are covalently attached to human AChE at three amino acid residues, whereas BuChE at nine asparagines. ¹² BChE has additional enzymatic activity, distinct from its esterase activity since it has an aryl acylamidase activity, catalyzing the hydrolysis of acyl amides of aromatic amines, and therefore is involved in functions other than cholinergic co-regulation. ¹²

The structure of Che changes when bound to a compound, differing it from its unbound form and impacting function and interactions.^30,31 Differences like this enable an understanding of how inhibitors function and how they can be optimized for future therapeutic purposes.^30,31 Changes in active site conformation depend on the Che structural difference.^30,31 Upon binding a compound, the active site of Che undergoes induced fit conformational changes to accommodate the ligand shifting the key residues affecting the active site pocket, where compound binding affects enzyme conformation and interaction, enhancing the binding affinity of the compound.^30,31 Binding can lead to the formation or disruption of hydrogen bonds between the enzyme and the compound. The bonds stabilize the compound within the binding site, changing overall conformation.^30,31 The charge distribution in the active site can change upon binding, leading to altered electrostatic interactions.^30,31 The compound may introduce new ionic interactions or modify existing ones, affecting enzyme stability and activity.^30,31 Bounding compounds may cause enzyme flexibility of ligand interaction, changing enzyme structure.^30,31 For example, in its free form, the active site of Che is more open and flexible.^30,31 When an inhibitor binds, the enzyme reduces access to other molecules, enhancing the specificity of the inhibitor.^30,31 Enzymes with multiple domains may exhibit shifts or rotations of domains upon compound binding. ³² These movements can change the relative positioning of different parts of the enzyme and influence its functional state. ³² Loops and helices near the binding site may adjust their positions to better interact with the compound, affecting form, dynamic, and complex stability. ³² In some cases, compound binding may induce allosteric changes in the enzyme, affecting regions distant from the active site and resulting in global conformational changes that impact the function. ³²

Dynamic studies using molecular dynamics simulations can reveal how the structure of Che evolves when bound to a compound.^33,34 These simulations can show how the conformation fluctuates and adapts during the binding process.^33,34 Enzyme catalytic activity can be enhanced or inhibited by binding a compound to a catalytic triad that is significant for hydrolytic activity. ³⁵ The structural changes upon compound binding can influence the binding affinity and specificity.^36,37 Higher affinity binding often correlates with more extensive structural rearrangements and tighter interactions. Structural differences can also impact the selectivity of different compounds.^36,37 Variations in binding modes and interactions can determine how well the enzyme recognizes and binds specific inhibitors or substrates.^36,37 Interaction with the inhibitor is dependent on the structural difference between Che enzymes. AChE features a deep active site gorge where the compound binds.^38,39 The structure of the gorge and the interactions with the compound can significantly affect enzyme activity.^38,39 AChE has distinct esteratic and anionic sites.^38,39 The binding of a compound can lead to changes in how these sites interact with the ligand, influencing the overall catalytic activity.^38,39 BChE typically has an active site compared to AChE.^40,41 The binding of compounds may involve different interactions due to this structural difference, affecting how the enzyme processes substrates and inhibitors.^40,41 BChE also has a peripheral binding site that can influence the activity and interaction with compounds, leading to structural changes in the enzyme upon binding.^40,41 The binding of a compound to Che can induce significant structural changes, including conformational shifts, alterations in side-chain positions, and modifications in binding site dynamics. These changes are crucial for understanding enzyme function, drug design, and the development of therapeutic agents targeting ChE, especially in neurodegenerative diseases.

Simulation of atomic and molecular physical movements over time, providing detailed insight into the dynamic behavior of macromolecules, is achieved by solving Newton’s equations of motion using the molecular dynamics (MD) computational method.^42,43 The potential energy associated with the system depends on mathematical description and force field parameters like length, angles, torsions, and non-bounded interactions covering a time scale from femtoseconds (10^–15 s) to microseconds (10^–6 s). ⁴⁴ Protein folding, conformational changes, and protein-ligand interactions are analyzed with MD using static data obtained from X-ray crystallography and NMR spectroscopy. ⁴⁵ Advanced MD methods enable the exploration of rare events to overcome the energy barriers of conventional methodology. ⁴⁵ These techniques enhance the exploration of conformational space and improve the accuracy of predictions. ⁴⁵ MD simulations integrate with experimental data to validate computational models and refine structural predictions, enabling an understanding of biological processes and designing potential therapists.^46,47 MD is a powerful tool for understanding molecular systems, which is significant and critical for drug discovery, structural biology, and biochemistry research.^46,47

Biogenesis, transport, processing and localisation of ChE enzymes

All forms of AChE are glycoproteins that can secrete or membrane-bound undergo similar secretory pathways. ¹⁵ Secretory pathways include synthesis and molecule binding, transport and secretion, localization and binding, traffic, and degradation. ¹⁵ Enzyme AChE synthesizes on a granular endoplasmic reticulum and undergoes co-translational glycosylation, adding asparagine-linked oligosaccharides to a growing polypeptide chain. ¹⁵ Enzyme AChE passes bending, assembling, and quality control before leaving the endoplasmic reticulum. ¹⁵ The Golgi apparatus translocates for further processing. ¹⁵ In the case of a collagen-bound form, coupling with a non-catalytic subunit is performed. ¹⁵ The binding of the PRIMA (proline-rich binding site) subunit was associated with the sensitivity of PRIMA-bound G4 AChE to endoglycosidase H. ¹⁵ The oligomeric form of AChE assembles and relocates to the appropriate cellular domain. ¹⁵ Molecular chaperones increase the activity of AChE in the granulated endoplasmatic reticulum, while the clathrin transport mechanism enables packing in the Golgi apparatus. ¹⁵ The main steps of biogenesis, transport, processing, and localization of AChE enzymes are present in Figure 6.OPEN IN VIEWER

The definition of the physiological role of the BChE is missing since it doesn’t have a single physiological substrate. Substrates interact with various endogenous substrates and xenobiotics like ACh, serving as a backup in ACh hydrolysis when inhibiting AChE. ⁴⁸

Molecular signalization and biological function

Cellular processes are affected by a complex network of biochemical and molecular reactions influencing gene expression through signaling pathways, receptors, signal transduction, effector molecules, and secondary messenger. ⁴⁹ AChE and BChE affect gene expression with various molecules within these particular signaling pathways. AChE has diverse roles and applications. For example, AChE has catalytic and non-catalytic functions leading to synaptic and nonsynaptic hydrolysis, terminating synaptic transmission, and expressing developmental and regenerative roles.^50,51 AChE is a potential disease biomarker, with increased expression during physiological stress, and is involved in cellular processes activating pathways like PI3K, MAPK, WNT/β-catenin, NF-κB, and many others involved in cell proliferation, differentiation, survival, and immune response.^29,52–58

MAPK/ERK signaling pathway is activated by receptor tyrosine kinases (RTKs) and G-protein coupled receptors (GPCRs), leading to sequential phosphorylation of MAP kinase kinases. ²⁹ The WNT/β-catenin pathway enables binding to Frizzled receptors and LRP5/6 co-receptors, while in the PI3K/Akt/mTOR pathway, PI3K activation leads to the generation of phosphatidylinositol-3,4,5-triphosphate (PIP3), recruits Akt to the cell membrane and activating mTOR.^29,52 NF-κB Signaling Pathway releases NF-κB dimers (p50/p65) from IκB inhibitors and causes translocation into the nucleus. ⁵⁷ These signaling pathways activate specific gene expression, leading to cell response.^29,52–58 The communication between pathways exists with negative and positive feedback, leading to the coordination of multiple signals. AChE interacts with diverse molecules within biochemical and molecular interactions like microRNA (miRNA), erythropoietin, and miRNA-132, leading to inflammatory response and gene expression.^29,52–58

AChE inactivates mitogen-activated protein kinase (MAPK) and PI3K/Akt pathways and activates GSK3ß in hepatocellular carcinoma (HCC) cells. ²⁹ Moreover, AChE can activate the JNK pathway and contribute to the activation of Apaf1, cytochrome c release, and Caspase 9. ²⁹ There are also indirect interactions with MAPK/PI3K pathways and potential involvement with the WNT/β-catenin signaling pathway. ⁵²

AChE downstream regulates microRNA-124 and modulates macrophage activation by inhibiting the STAT3 signaling pathway in patients with bowel failure. ⁵³ Downstream regulation of erythropoietin regulates the expression of the AChE dimeric form during erythroblast differentiation, affecting protein function through the interaction of AChE with the erythropoietic receptor. ⁵⁴ Erythropoietin regulates the expression of the dimeric form of AChE during erythroblast differentiation. ⁵⁵ Based on analyses using online tools and a luciferase reporter assay, miR-132 protects Ach from degradation by ACHE, where miR-132 exerts favorable effects on CNS neurons via brain-derived neurotrophic factors (BDNF). ⁵⁶ Regarding inflammation and Gene Expression contributing to cholinergic function and disease is inhibition of AChE, which leads to the attenuation of retinal inflammation via NF-κB suppression, and upstream regulation leads to Early Growth Response 1 (ERG1) affecting transcription.^57,58

BChE has a non-specific function and influences nervous system development due to structural similarities between AChE and BChE and cell adhesion molecules with the possible non-catalytic role. The enzyme BChE is a serine hydrolase. It catalyzes the hydrolysis of choline esters like butyrylcholine, succinylcholine, and acetylcholine. Hydrolysis of acetylcholine is less efficient than AChE. ¹² BChE influences PKC/ERK pathways in R28 cancer cells, immune response pathways, transforming growth factor-β (TGF-β) signaling, and cancer immunotherapy via PD1 blockade pathways.^59,60 BChE expression positively correlates with CD28, ADORA2A, BTNL2, and TNFRSF18. ⁶⁰ BChE expression is under regulation by iron through Iron Response Elements (IREs) in the 3′-UTR, where under low iron conditions, IRP1 and IRP2 bind to the IREs, stabilizing BChE mRNA, preventing degradation, and increasing BChE levels. ⁶¹ A positive correlation exists between BChE activity and red blood cell (RBC) count, Figure 7. ⁶¹ Erythropoietin (EPO) synthesis increases through iron-regulated transcriptional activation. ⁶¹ When iron levels rise, HIF-2α mediates EPO gene transcription, indirectly regulated by IRP interactions with IREs in BChE mRNA. ⁶¹ The lifetime of RBCs is about 100–120 days. The aging RBCs undergo eryptosis and programmed death. ⁶¹ Much of the breakdown products recirculate by the spleen and the liver. The iron is released into the plasma to be recirculated by protein transferrin (Tf). ⁶¹ Thus, the recirculated Tf-bound iron (TBI) is proportional to the RBC count. Transferrin receptor protein 1 regulates serum BChE biosynthesis by IRPs in the liver. ⁶¹ EPO synthesis is triggered by the transcriptional activation induced by iron, leading to an upregulation of erythropoiesis. ⁶¹ EPO gene transcriptional activation mediates by binding HIF-2α to the hypoxia response element. ⁶¹ As iron levels rise, IRP1 cannot bind to the IRE sequence at the 5′-UTR of HIF-2α. This results in an increase in EPO due to the extended translation of HIF-2α. Based on this information, levels of BChE and RBC represent the cellular iron concentration or TBI. ⁶¹ OPEN IN VIEWER

The putative IRE occurs in the 3’-UTR of BChE and the 5’-UTR. ³⁸ The consensus IRP binding sequence resides in the 5’-UTR region. ⁶¹ Under high iron cell concentrations, the IRPs cannot bind the IREs. IRPs bind to IRE at the 5’-UTR of mRNA and inhibit translation inhibition by preventing ribosome binding to the mRNA. ⁶¹ Binding IRPs to IREs at the 3’-UTR prevents mRNA degradation and endonucleolytic cleavage by decreasing mRNA levels. ⁶¹ Based on this information, BChE expression is positively regulated by iron in the 5’-UTR IRE element and 3-UTR by one stem loop with additional regulator factors as a negative feedback mechanism. More testing will be needed to validate this hypothesis. ⁶¹

Disease mechanism research depends on a choice model system (in vivo, in vitro) to validate disease signaling biomarkers. Bioinformatics and Systems Biology enable modeling and simulation of signaling networks, analyze high-throughput data, and predict pathway interactions and dynamics in a cost-effective, fast, and precise way. Clinical application of AChE and BChE inhibitors arise from a multidisciplinary scientific approach, combining knowledge.

Polymorphisms

AChE enzyme polymorphism is present in the eggs and sperm of different species.^62,63 AChE acts as a signaling receptor during hematopoiesis, protein adhesion, amyloid fiber formation, neurite outgrowth, bone development, and maturation.^62,63 Roles from the above explain the nonsynaptic hydrolysis of the AChE enzyme. So far, to present knowledge, 35 gene variations of clinical significance (pathogenic, benign, and unknown) exist. The list provided by the National Library of Medicine and the National Center for Biotechnology Information is available in Supplemental File 1. By 2005, an accurate estimate of the genetic polymorphism (Single Nucleotide Polymorphism_SNP) of the AChE gene in the healthy population was called into question. ⁶⁴ There was a limitation of ethnic groups, a small number of respondents, and incomplete coverage of the AChE coding region. ⁶⁴ There were 18 SNPs on the list, of which 13 lacked biological validation of population frequency. ⁶⁴ Some SNPs are harmful due to amino acid substitution. ⁶⁴ Clinically significant polymorphisms include the distal portion of the AChE promoter and the His 322 substitution. ⁶⁴ Polymorphism of the distal part of the AChE promoter (substitution T> A) interrupts or interferes with the glucocorticoid response. ⁶⁴ It is associated with acute susceptibility to anticholinesterase agents (pesticides). ⁶⁴ Essential for the development of Gulf War syndrome. ⁶⁴ Substitution of the amino acid His 322 with Asp is responsible for the YT-2 phenotype of the blood group, which is a significant factor for matching donor and recipient blood groups. ⁶⁴ CDNA change: c. 1057 C>A in protein (Histidine 353 with Asparafine) does not affect function. ⁶⁴ In 2005, researchers identified 13 SNPs in the AChE gene within various ethnic groups and explored their possible effects on the structure and function of AChE. ⁶⁴ Moreover, amino acid substitutions exist (Arginine 34Glicine, Glycine57Arginin, Glutamine 344Glycine, Histidin353Asparagin, Proline 592Arginine). ⁶⁴ The basis for the functional and pharmacogenetics of natural AChE protein variants has been established. ⁶⁴ The detected SNPs assess the involvement of occurring AChE polymorphisms during the disease mechanism and different drug responses. ⁶⁴ AChE HN353N protein polymorphism is associated with a low prognosis of chronic Chaga disease. ⁶⁵ The intron point mutation AChE rs2571598 has C / T substitution. ⁶³ It affects enzyme activity and therapeutic response in patients with Alzheimer’s disease (AD) and increases AChE activity in patients with multiple sclerosis. ⁶³ A variant of the rs17228602 enzyme AChE is associated with drug dependence, such as hashish and heroin. ⁶⁶ Polymorphism rs17228616 in the AChE gene enables overcoming the post-traumatic stress symptom correlated with the co-intensified emotional response of the amygdala and ventromedial prefrontal cortex. ⁶⁷ This SNP disrupts the suppression of AChE miRNA-608, increases AChE in the brain, and decreases cortisol and a miRNA-608 targeted GABAergic modulator CDC42, which is associated with stress in soldiers. ⁶⁷ A correlation exists between miRNA-608, CD44, CDC42, and interleukin 6 expression levels in the human amygdala. ⁶⁷ The role of synaptic AChE in β-amyloid deposition and aggregation in individuals with AD has been demonstrated. ⁶⁸ Prolonged exposure to electromagnetic waves (Wi-Fi) changes gene expression, behavioral patterns, and neurodegenerative diseases. ⁶⁹ Primor-specific recognition of polymorphism of the primate-specific miRNA-608 element in the 3’ untranslated region of the AChE transcript increases the level of AChE in the brain during anxious and inflammatory reactions accompanied by disturbances in the regulatory network of non-coding RNA (CholinomiRs-608). ⁷⁰ The genetic polymorphism of the nicotinic cholinergic receptor α7 (CHRNA7) and CHRNA7 (CHRFAM7A) genes is a possible susceptibility trait for dementia. ⁷¹

The enzyme AChE is a target for chemical warfare. ⁷² The enzyme AChE applies organophosphate, carbamate, food poisoning, disease diagnosis, therapy, and treatment.^72,73 The enzyme AChE is a marker of the aging process. ⁷⁴

Mutations in BChE produce a range of enzyme catalytic activity. The wild-type BuChE (BuChE-WT) is sensitive to dibucaine inhibition. Atypical BChE variant with a mutation at codon 70 causes the substitution of aspartic acid for a glycine residue (D70G) which leads to insensitive inhibition by dibucaine, where some show apnoea after administration of succinylcholine or ingestion of the cholinesterase inhibitor pyridostigmine including severe depression, insomnia and profound weight loss, pointing to effects of the mutation in both the central and the peripheral nervous systems. ¹² K variant mutation has a mutation at codon 539 that leads to the replacement of an alanine by a threonine residue (A539T)76 and has about 33% lower enzymatic activity relative to BuChEWT. J mutation variant results from a mutation at codon 497, which changes a glutamic acid residue to valine (E497V)78, leading to 66% lower enzymatic activity about BuChE-WT. H variant has a valine residue at codon 142 replaced by a methionine (V142M), resulting in a protein with 90% lower activity than the wild-type enzyme. ¹² Fluoride inhibits BuChE-WT, and two fluoride-resistant forms exist. At first, threonine at codon 243 changes to methionine (T243M). Secondly, glycine at codon 390 shifts by valine (G390V). Finally, there is the Silent variant, where there are at least 12 additional mutant forms of BuChE with no known activity, and they can’t catalyze the hydrolysis of choline esters.

Allelic frequencies of the W, K, and atypical forms of BuChE reports being about 85%, 10%, and 13%, with some people carrying double mutations (K and A), whereas other BuChE mutations are present in much lower frequencies. The reliability of these frequency estimates has to be confirmed, as differences in allelic frequencies are present within various ethnic populations. ¹² On the other hand, the allelic frequency of the atypical variant is higher in populations from areas where plants of the Solanaceae family are Indigenous, favoring the natural selection of people resistant to poisoning through diet. The functional consequences of most of these variants are not well known. Neurodegenerative disease relates to the K variant. ¹²

Factors that influence enzyme AChE

The quality of life depends on factors affecting health that are under/out of the control of the individual. Disease in the population is cured and eradicated by discovering factors leading to the illness and applying suppression methods. Detection of factors includes consideration of the current situation in the population, diagnosis, understanding of the impact on disease onset and death, monitoring of health status, detection of the causes of disease and death, application of measures to prevent and control the outcome and assessment measures for disease control and eradication. Numerous environmental factors influence the prognosis and incidence of the disease in both developed and developing countries. The most significant factors are biological characteristics of the organism and genetics (hereditary diseases), public policies and regulations (vaccination campaigns), health (financing, diagnosis, and treatment of diseases), life habits (smoking, physical activity, hydration of the organism), social and environmental factors (crime, environmental pollution).^110,111 Today it is known that the onset and course of the disease require the combined action of various environmental factors. Studies on ChE levels generally examine genetic variability, health conditions, and exposure to specific chemicals, which can influence enzyme levels in different populations. For example, cholinesterase tests assess exposure to organophosphates and diagnose certain liver conditions, and results can vary widely based on individual health and genetic background. ¹¹² Muslims suffer more from contagious jaundice and spotted fever and less often from trichinosis because they do not eat pork. ¹¹³ There is no statistically significant relation between alcohol consumption habits and the intra-racial difference in BChE activity between the Black and non-black population in Salvador, Bahia. There are statistically significant differences between genders and age groups within the Salvador, Bahia population. However, other communities show interracial differences between white and black people. ¹¹⁴ Disease diversity depends on biological characteristics, environment, and habits. ¹¹⁵ Enzyme AChE activity decreases due to chemical exposure for tea cultivation and agriculture.^110,111 Moreover, the enzymes AChE and BChE change depending on the profession.^112,116

Residents who smoke or consume drugs due to religious or religious customs, such as Indians, have a higher risk of cancer. ¹¹⁵ Cigarette consumption affects AChE and not BChE activity.^117,118 Smoking leads to blood and urine biomarker changes.^119,120 Drug addicts show the involvement of AChE and BChE depending on the substrate.^66,121 Alcohol consumption affects the activity of the enzyme AChE and its concentration. ¹²² This information addresses different aspects of ChE activity, focusing on demographic differences and examining the impact of smoking, providing valuable insight into factors influencing ChE activity.

In situations with life-threatening cocaine-induced cardiovascular failure, enzyme BChE is an effective and fast therapy. ¹²³ There was no relationship between alcohol use and lower BChE activity (p = .725, Mann–Whitney). Women using hormonal contraceptives had an activity median of 9.2% lower than the non-users. ¹¹⁴

Food consumption influences the immune system of an organism. ¹²⁴ Insufficient vitamins, minerals, proteins, fats, and carbohydrates can lead to disease. ¹²⁴ Dairy foods such as potatoes, tomatoes, peppers, strawberries, broccoli, and carrots contain natural cholinesterase inhibitors. ¹²⁵

Drugs have different effects on biomarker activity. ¹²⁶ For example, AChE inhibitors apply to quit smoking.^127–129 Sulfonamide derivatives are good candidates for novel AChE inhibitors. Sulfonamides have low cytotoxicity and tumor selectivity in oral squamous cell carcinoma. ¹³⁰ AChE enzyme inhibitors kill disease vectors such as mosquitoes. ¹³¹ Air pollution reduces AChE activity. ¹³² Water pollution influences the AChE range. ¹³³ Oil spillage can lead to the inhibition of the AChE enzyme. ¹³⁴

During World War II, the Germans weaponized nerve agents utilizing phosphonofluoridate-based nerve toxins like sarin, soman, and tabun dispersed through the air, inhibiting the AChE. ⁷²

An important consideration and future perspectives

Analytical techniques detect and quantify AChE inhibitors and their metabolites in blood, urine, and cerebrospinal fluid samples.^143,144 It is one decade of techniques in the research practice, enabling the detection of simultaneous changes in the organism during homeostatic and pathological organism states. Changes in enzyme AChE concentration and structure are specific. Enable the development of potential drug target molecules. A series of experiments in vitro human blood samples can show that enzyme AChE activity and inhibitor inhibition efficacy change in plasma, erythrocyte, and whole blood fraction, depending on pre-analytical factors like time of freezing, the temperature of freezing, sample frequency, physical activity, and water intake. Investigating the effect of pre-analytical factors is significant for proper result interpretation. Enzyme AChE is not a generic marker of extracellular vesicles, meaning that AChE activity and inhibition in blood fractions are reliable blood biomarkers. ¹⁴⁵ Blood fractions enriched with AChE participate in inflammatory processes during health and disease, membrane integrity, aging, gender differences, neurotoxicity, and pesticide poisoning. ¹⁴⁶

The primary task of developing countries is to improve health outcomes and disease eradication by providing high-quality health care using available drugs. Increasing the effectiveness of drugs and connecting and understanding the physiological changes of the organism due to environmental factors will improve the quality of the market. Creating a new clinical and scientific chain system that uses ingredients, permitted doses, and is safe to work with humans improves drug access and increases safety.

The plan for further scientific analysis in this area includes increasing the research value by conducting a systematic analysis with guiding steps. An up-to-date literature review of existing experimental and computational findings will enable the revealing of potential inconsistencies and gaps with further validation and research development. The literature review encompasses experimental protocols and statistical data analysis to validate the information from the materials and methods section and deepen the understanding of current research. Collaboration with interdisciplinary experts will enable rigor and robust methodology validation of the experimental result designs. To further understand the action mechanism for BChE/AChE inhibition series of compounds, the kinetic assay and molecular docking studies determine the optimal composite. The inhibition assay should evaluate a range of bioactive compounds and natural products to assess their potential to inhibit AChE and BChE enzymes, thereby facilitating their clinical application in disease treatment. Before clinical application in vivo, models provide pharmacokinetic properties and investigate clinical performance. A combination of biochemical, molecular biological, genetic, and molecular docking studies will allow the identification of crucial compounds and specific genomic and biochemical locations for disease treatment. Providing extensive data will help develop models capable of predicting the effects and clinical efficacy of AChE and BChE inhibitors.

Structural analysis with X-ray crystallography and NMR spectroscopy will validate protein-protein interactions and detect structural changes to validate existing findings. The objective would be to increase the robustness and reliability of data by designing and executing an experimental approach with computational methodology. However, future experimental validation should include patients with AD and MG from patients. In silico studies of potential biomarkers in neurodegenerative diseases and neurotoxicity are currently under review. Potential computational methodology should investigate and confirm the findings from the literature and experiments. Accuracy and reliability of computational models with approaches like molecular dynamics simulations by extending simulation times (from nanoseconds to microseconds) improve sampling stability and validate simulation results by comparing root mean square deviations (RMSD) of enzyme structures against experimental results or known structures, quantum mechanics calculations to refine the understanding of reaction mechanisms and binding energies of inhibitor-enzyme complexes and to study enzymatic reaction mechanisms involving cholinesterase inhibitors, and force field optimization for fine-tune force field parameters (partial charges, van der Waals parameters) based on experimental validation or community standard, and comparing force field with an experimental observation like binding affinities and structural stability with GROMACS. The computational analysis should validate and refine computational models and simulations comparing predictions with experimental results.